凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
广誉远(600771)公告正文

广誉远:2018年第三季度报告

公告日期 2018-10-27
股票简称:广誉远 股票代码:600771
公司代码:600771                              公司简称:广誉远




            广誉远中药股份有限公司
                   2018 年第三季度报告




                     二○一八年十月二十七日
                                                                 广誉远中药股份有限公司 2018 年第三季度报告




                                                        目       录



一、重要提示 ...........................................................................................................2

二、公司基本情况 ....................................................................................................2

三、重要事项 ...........................................................................................................5

四、附录 ..................................................................................................................7




                                                             1
                                                       广誉远中药股份有限公司 2018 年第三季度报告



一、 重要提示


1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、

    完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和连带的法律责任。

1.2 公司全体董事出席董事会审议季度报告。

1.3 公司负责人张斌、主管会计工作负责人傅淑红及会计机构负责人(会计主管人员)

    侯宽余保证季度报告中财务报表的真实、准确、完整。



1.4 本公司第三季度报告未经审计。


二、 公司基本情况
2.1 主要财务数据
                                                                                单位:元   币种:人民币

                                                                                    本报告期末比
                               本报告期末                    上年度末
                                                                                   上年度末增减(%)

总资产                       2,708,084,949.57                2,517,620,674.29                        7.57

归属于上市公司股东的净资产   2,125,748,199.94                1,913,826,432.98                      11.07

                             年初至报告期末            上年初至上年报告期末
                                                                                  比上年同期增减(%)
                               (1-9 月)                   (1-9 月)

经营活动产生的现金流量净额    -269,909,092.42                 -226,170,621.32                      不适用

                             年初至报告期末            上年初至上年报告期末
                                                                                 比上年同期增减(%)
                               (1-9 月)                   (1-9 月)

营业收入                     1,021,622,356.72                  737,759,372.65                      38.48

归属于上市公司股东的净利润     225,978,885.45                  103,593,685.26                    118.14

归属于上市公司股东的扣除非
                               223,636,211.67                   94,915,556.15                    135.62
经常性损益的净利润

加权平均净资产收益率(%)               11.15                            5.89        增加 5.26 个百分点

基本每股收益(元/股)                       0.64                         0.29                    120.69

稀释每股收益(元/股)                       0.64                         0.29                    120.69



非经常性损益项目和金额
√适用 □不适用

                                                   2
                                                                  广誉远中药股份有限公司 2018 年第三季度报告


                                                                                                     单位:元      币种:人民币
                                                                                     本期金额            年初至报告期末金
                                   项目
                                                                                    (7-9 月)               额(1-9 月)

非流动资产处置损益                                                                          -522.84               -39,800.54

越权审批,或无正式批准文件,或偶发性的税收返还、减免                                                             280,100.00

计入当期损益的政府补助,但与公司正常经营业务密切相关,符合国
                                                                                                                1,207,208.90
家政策规定、按照一定标准定额或定量持续享受的政府补助除外

委托他人投资或管理资产的损益                                                                                    2,625,000.00

除上述各项之外的其他营业外收入和支出                                                    -802,696.49              -780,770.71

少数股东权益影响额(税后)                                                               42,151.32               -356,646.43

所得税影响额                                                                              -1,500.00              -592,417.44

                                   合计                                                 -762,568.01             2,342,673.78



2.2 截止报告期末的股东总数、前十名股东、前十名流通股东(或无限售条件股东)持
     股情况表
                                                                                                                         单位:股

                             股东总数(户)                                                          18,382

                                                    前十名股东持股情况

                                                                             持有            质押或冻结情况
                  股东名称                          期末           比例
                                                                           有限售条件                                  股东性质
                  (全称)                        持股数量         (%)                    股份状态       数量
                                                                           股份数量

西安东盛集团有限公司                             81,759,323        23.17   27,711,058       质押      53,560,000     境内非国有法人

财富证券-浦发银行-财富证券-广誉远安宫清心集合
                                                 16,000,000         4.53                    无                           其他
资产管理计划

宁波鼎盛金禾股权投资合伙企业(有限合伙)         12,701,533         3.60   12,701,533       无                           其他

华能贵诚信托有限公司-华能信托悦晟 3 号单一资
                                                 11,899,067         3.37                    无                           其他
金信托

全国社保基金一零四组合                           11,619,848         3.29                    无                           其他

国寿安保基金-建设银行-人寿保险-中国人寿保险
                                                 10,599,521         3.00                    无                           其他
(集团)公司委托国寿安保基金混合型组合

樟树市磐鑫投资管理中心(有限合伙)               10,161,227         2.88   10,161,227       无                           其他

北京东富新投投资管理中心(有限合伙)              8,134,129         2.31                    无                           其他

郑文平                                            7,250,103         2.05                    无                        境内自然人

蒋仕波                                            6,210,000         1.76                    无                        境内自然人

                                                前十名无限售条件股东持股情况




                                                              3
                                                                  广誉远中药股份有限公司 2018 年第三季度报告


                                                                    持有无限售条件                   股份种类及数量
                         股东名称
                                                                     流通股的数量                种类                 数量

西安东盛集团有限公司                                                       54,048,265        人民币普通股             54,048,265

财富证券-浦发银行-财富证券-广誉远安宫清心集合资产管理计划                  16,000,000        人民币普通股             16,000,000

华能贵诚信托有限公司-华能信托悦晟 3 号单一资金信托                         11,899,067        人民币普通股             11,899,067

全国社保基金一零四组合                                                     11,619,848        人民币普通股             11,619,848

国寿安保基金-建设银行-人寿保险-中国人寿保险(集团)公司委托
                                                                           10,599,521        人民币普通股             10,599,521
国寿安保基金混合型组合

北京东富新投投资管理中心(有限合伙)                                           8,134,129     人民币普通股              8,134,129

郑文平                                                                         7,250,103     人民币普通股              7,250,103

蒋仕波                                                                         6,210,000     人民币普通股              6,210,000

长安国际信托股份有限公司-长安信托-广誉远第二期员工持股集合
                                                                               6,205,619     人民币普通股              6,205,619
资金信托计划

长安基金-广发银行-华鑫信托-鑫康财富 6 号单一资金信托                           4,535,799     人民币普通股              4,535,799


                                                                  华能贵诚信托有限公司-华能信托悦晟 3 号单一资金信托所持股份系公

                                                                  司控股股东西安东盛集团有限公司间接增持股份,长安国际信托股份有

                                                                  限公司-长安信托-广誉远第二期员工持股集合资金信托计划所持股份为

                                                                  公司员工持股计划所购买股票,除此之外东盛集团与其他股东之间无关
上述股东关联关系或一致行动的说明
                                                                  联关系;宁波鼎盛金禾股权投资合伙企业(有限合伙)与樟树市磐鑫投

                                                                  资管理中心(有限合伙)之间有关联关系,其他股东之间公司未知是否

                                                                  存在关联关系,也未知是否属于《上市公司收购管理办法》中规定的一

                                                                  致行动人。




2.3 截止报告期末的优先股股东总数、前十名优先股股东、前十名优先股无限售条件股
     东持股情况表
□适用 √不适用



三、 重要事项

3.1 公司主要会计报表项目、财务指标重大变动的情况及原因
√适用 □不适用


                                                                                                              单位:元




                                                              4
                                             广誉远中药股份有限公司 2018 年第三季度报告


                  项目             期末余额             年初余额         变动比例(%)

   应收票据及应收账款          1,250,798,645.84         978,161,693.10            27.87

   预付账款                         50,986,583.33        12,936,480.96           294.13

   其他应收款                      120,749,021.77        87,050,566.59            38.71

   存货                            286,026,536.06       182,357,154.76            56.85

   其他流动资产                      6,153,573.49       307,601,990.42           -98.00

   固定资产                        473,024,040.15        54,612,552.13           766.15

   在建工程                        149,740,924.88       456,875,509.98           -67.23

   开发支出                          2,131,519.93         4,567,571.86           -53.33

   其他非流动资产                   34,140,362.15        19,197,966.15            77.83

   短期借款                        189,721,750.00       110,000,000.00            72.47

   应付账款                        109,703,815.93       166,463,548.20           -34.10

   应付职工薪酬                      6,008,976.03        14,388,536.36           -58.24

   应交税费                         52,472,980.48        93,923,861.32          -44.13



    (1)应收票据及应收账款比期初增加27,263.70万元,增幅27.87%,主要因为报告
期营业收入增加使得信用期内应收账款增加33,155.57万元及期末应收票据较期初减少
5,891.88万元综合所致。
    (2)预付账款比期初增加3,805.01万元,增幅294.13%,主要因为预付的广告费和
设备款增加。
    (3)其他应收款比期初增加3,369.85万元,增幅38.71%,主要因为报告期拨付的
市场备用金及其他业务往来款增加。
    (4)存货比期初增加10,366.94万元,增幅56.85%,主要因为报告期公司利用中药
材市场价格波动,对牛黄、穿山甲片、天然麝香等贵细药材进行储备性采购,增加原材
料8,064.14万元,以及为市场销售备货增加库存商品2,317.33万元。
    (5)其他流动资产比期初减少30,144.84万元,减幅98.00%,主要因为报告期山西
广誉远收回到期的结构性存款产品30,000万元。
    (6)固定资产比期初增加41,841.15万元,增幅766.15%,在建工程比期初减少
30,713.46万元,减幅67.23%,主要因为报告期山西广誉远对新建中医药产业项目及中
药技术研发中心项目中的41,590.60万元结转固定资产所致。




                                         5
                                                广誉远中药股份有限公司 2018 年第三季度报告


    (7)开发支出比期初减少243.61万元,减幅53.33%,主要因为报告期北京杏林誉
苑结转杏林壹号APP的延伸开发计入无形资产。
    (8)其他非流动资产比期初增加1,494.24万元,增幅77.83%,主要因为报告期公
司影视剧投资1,920万元所致。
    (9)短期借款比期初增加7,972.18万元,增幅72.47%,主要因为山西广誉远新增
借款7,972.18万元。
    (10)应付账款比期初减少5,675.97万元,减幅34.10%,主要因为支付前期应付材
料款及工程款。
    (11)应付职工薪酬比期初减少837.96万元,减幅58.24%,主要因为报告期支付
上期预提工资薪金。
    (12)应交税费比期初减少4,145.09万元,减幅44.13%,主要因为报告期缴纳了年
初应交的增值税、所得税及其他相关税费。
                                                                                  单位:元

                  项目                本期数              上年同期数        变动比例(%)

   经营活动产生的现金流量净额        -269,909,092.42      -226,170,621.32           不适用

   投资活动产生的现金流量净额        126,603,309.85       -488,911,132.46           不适用

   筹资活动产生的现金流量净额         62,291,339.72        -10,420,678.32           不适用

   营业收入                         1,021,622,356.72       737,759,372.65            38.48

   财务费用                             9,036,396.86         1,913,053.98           372.35

   资产减值损失                       10,845,249.49          4,089,527.06           165.20

   营业外收入                           1,064,308.90         6,767,306.80           -84.27

   所得税费用                         44,157,732.56         33,809,756.11            30.61

   利润总额                          280,902,661.83        143,621,009.23            95.59

   净利润                            236,744,929.27        109,811,253.12           115.59

   归属于母公司所有者权益的净利润    225,978,885.45        103,593,685.26           118.14



    (1)经营活动产生的现金流量净额比上年同期减少4,373.85万元,主要因为①随着
收入的增长,经营活动收到的现金比去年增加4,099.79万元,但收到的其他与经营活动
有关的政府款项、保证金等比去年同期减少6,238.71万元,使得公司经营性现金流入较
上年同期减少2,110.91万元;②报告期内,经营性现金流出较上年同期净增加2,262.94
万元,主要是由于公司销售增长导致缴纳的增值税增加以及销售投入加大,合计净增加



                                            6
                                           广誉远中药股份有限公司 2018 年第三季度报告


8,061.95万元;③报告期内,经营性现金流入的减少以及流出的增加,综合使得公司经
营净现金流量比上年同期减少4,373.85万元。
    (2)投资活动产生的现金流量净额比上年同期增加61,551.44万元,公司收回利用
闲置募集资金所购买理财产品的本金和利息所致。
    (3)筹资活动产生的现金流量净额比上年同期增加7,271.20万元,主要因为报告期
山西广誉远在光大银行及平安银行新增借款7,972.18万元。
    (4)营业收入比上年同期增加28,386.30万元,增幅38.48%,主要因为报告期公司
持续扩大市场销售,加强终端促销和学术推广,品牌效应进一步释放,使得公司各业务
板块销售收入进一步提升。
    (5)财务费用比上年同期增加712.33万元,增幅372.35%,主要因为山西广誉远
短期借款增加7,972.18万元,使得利息支出相应增加。
    (6)资产减值损失比上年同期增加675.57万元,增幅165.20%,主要因为报告期
应收款项增加,公司按照会计政策计提相应的坏账准备。
    (7)营业外收入比上年同期减少570.30万元,减幅84.27%,主要因为上年同期拉
萨广誉远收到政府补助612.04万元。
    (8)所得税费用、利润总额、净利润和归属于母公司所有者的净利润分别较上年
同期增加1,034.80万元、13,728.17万元、12,693.37万元和12,238.52万元,增幅为
30.61%、95.59%、115.59%和118.14%,主要因为:①报告期营业收入比上年同期增
长38.48%;②公司持续加强生产管理、实施成本控制,同时合理规划贵细药材采购,使
得报告期毛利率增加2.32个百分点。


3.2 重要事项进展情况及其影响和解决方案的分析说明
□适用 √不适用


3.3 报告期内超期未履行完毕的承诺事项
□适用 √不适用


3.4 预测年初至下一报告期期末的累计净利润可能为亏损或者与上年同期相比发生重大
   变动的警示及原因说明
√适用 □不适用


                                       7
                                         广誉远中药股份有限公司 2018 年第三季度报告


   随着“好孕中国”、“撒网行动”等各项市场活动的深入开展以及社会化营销的积
极创新和广告的多元化精准投放,公司的核心优势以及品牌的认知度和美誉度持续提升,
进一步带动了销售的持续增长。同时,公司加强采购管理,严把成本控制,提升管理效
率,使得盈利能力进一步提高,故预计年初至下一报告期期末的累计净利润与上年同期
相比将大幅提升。




                                           公司名称      广誉远中药股份有限公司
                                           法定代表人    张斌
                                           日期          2018 年 10 月 26 日




                                     8
                                                     广誉远中药股份有限公司 2018 年第三季度报告


四、 附录
4.1 财务报表

                                        合并资产负债表
                                         2018 年 9 月 30 日

编制单位:广誉远中药股份有限公司
                                                              单位:元   币种:人民币   审计类型:未经审计

                      项目                                 期末余额                      年初余额

流动资产:
 货币资金                                                      199,931,767.31              280,946,210.16

 结算备付金

 拆出资金

 以公允价值计量且其变动计入当期损益的金融资产

 衍生金融资产

 应收票据及应收账款                                           1,250,798,645.84             978,161,693.10

 其中:应收票据                                                183,879,573.63              242,798,351.87

        应收账款                                              1,066,919,072.21             735,363,341.23

 预付款项                                                       50,986,583.33               12,936,480.96

 应收保费

 应收分保账款

 应收分保合同准备金

 其他应收款                                                    120,749,021.77               87,050,566.59

 其中:应收利息                                                                              2,929,166.67

        应收股利

 买入返售金融资产

 存货                                                          286,026,536.06              182,357,154.76

 持有待售资产

 一年内到期的非流动资产

 其他流动资产                                                     6,153,573.49             307,601,990.42

   流动资产合计                                               1,914,646,127.80           1,849,054,095.99

非流动资产:

 发放贷款和垫款

 可供出售金融资产                                               18,300,000.00               18,300,000.00

 持有至到期投资

 长期应收款

 长期股权投资                                                     6,027,256.45               7,530,627.34




                                                 9
                                                 广誉远中药股份有限公司 2018 年第三季度报告


 投资性房地产

 固定资产                                                473,024,040.15          54,612,552.13

 在建工程                                                149,740,924.88         456,875,509.98

 生产性生物资产

 油气资产

 无形资产                                                 95,909,471.83          93,646,874.29

 开发支出                                                   2,131,519.93           4,567,571.86

 商誉

 长期待摊费用                                             11,192,392.58          11,059,175.77

 递延所得税资产                                             2,972,853.80           2,776,300.78

 其他非流动资产                                           34,140,362.15          19,197,966.15

   非流动资产合计                                        793,438,821.77         668,566,578.30

     资产总计                                           2,708,084,949.57       2,517,620,674.29

流动负债:

 短期借款                                                189,721,750.00         110,000,000.00

 向中央银行借款

 吸收存款及同业存放

 拆入资金

 以公允价值计量且其变动计入当期损益的金融负债

 衍生金融负债

 应付票据及应付账款                                      113,354,175.93         171,100,613.65

 预收款项                                                 29,082,265.12          23,002,143.13

 卖出回购金融资产款

 应付手续费及佣金

 应付职工薪酬                                               6,008,976.03         14,388,536.36

 应交税费                                                 52,472,980.48          93,923,861.32

 其他应付款                                               83,389,131.94          91,932,278.03

 其中:应付利息                                                                     164,937.50

        应付股利

 应付分保账款

 保险合同准备金

 代理买卖证券款

 代理承销证券款

 持有待售负债

 一年内到期的非流动负债

 其他流动负债



                                                10
                                                   广誉远中药股份有限公司 2018 年第三季度报告


   流动负债合计                                                474,029,279.50            504,347,432.49

非流动负债:

  长期借款

  应付债券

  其中:优先股

         永续债

  长期应付款                                                     8,820,000.00              8,820,000.00

  长期应付职工薪酬

  预计负债

  递延收益                                                      15,361,133.33             14,323,633.33

  递延所得税负债

  其他非流动负债                                                10,000,000.00             10,000,000.00

   非流动负债合计                                               34,181,133.33             33,143,633.33

     负债合计                                                  508,210,412.83            537,491,065.82

所有者权益(或股东权益)

  实收资本(或股本)                                           352,878,988.00            353,111,304.00

  其他权益工具

  其中:优先股

         永续债

  资本公积                                                 1,754,022,629.96            1,753,790,314.96

  减:库存股

  其他综合收益

  专项储备

  盈余公积                                                      29,615,319.69             29,615,319.69

  一般风险准备

  未分配利润                                                   -10,768,737.71           -222,690,505.67

  归属于母公司所有者权益合计                               2,125,748,199.94            1,913,826,432.98

  少数股东权益                                                  74,126,336.80             66,303,175.49

   所有者权益(或股东权益)合计                            2,199,874,536.74            1,980,129,608.47

     负债和所有者权益(或股东权益)总计                    2,708,084,949.57            2,517,620,674.29




法定代表人:张斌                  主管会计工作负责人:傅淑红                    会计机构负责人:侯宽余




                                                 11
                                            广誉远中药股份有限公司 2018 年第三季度报告


                                  母公司资产负债表
                                   2018 年 9 月 30 日
编制单位:广誉远中药股份有限公司

                                                          单位:元   币种:人民币   审计类型:未经审计

                      项目                              期末余额                    年初余额

流动资产:

 货币资金                                                 13,300,929.16                17,318,905.84

 应收票据及应收账款

 其中:应收票据

        应收账款

 预付款项

 其他应收款                                              602,831,137.12               675,561,687.10

 其中:应收利息

        应收股利

 存货

 持有待售资产

 一年内到期的非流动资产

 其他流动资产

   流动资产合计                                          616,132,066.28               692,880,592.94

非流动资产:

 可供出售金融资产                                         10,000,000.00                10,000,000.00

 持有至到期投资

 长期应收款

 长期股权投资                                           2,214,062,637.83            2,200,912,637.83

 投资性房地产

 固定资产                                                   2,036,457.68                2,045,231.51

 在建工程

 生产性生物资产

 无形资产

 开发支出

 商誉

 长期待摊费用

 递延所得税资产

 其他非流动资产                                           19,200,000.00

   非流动资产合计                                       2,245,299,095.51            2,212,957,869.34

     资产总计                                           2,861,431,161.79            2,905,838,462.28

流动负债:




                                          12
                                                    广誉远中药股份有限公司 2018 年第三季度报告


  短期借款

  应付票据及应付账款                                              2,142,289.77                2,142,289.77

  预收款项                                                        4,187,444.75              115,836,622.85

  应付职工薪酬                                                      750,759.80                  744,249.36

  应交税费                                                          800,829.46                  502,740.22

  其他应付款                                                      6,088,859.08                6,835,547.45

  其中:应付利息

       应付股利

  一年内到期的非流动负债

  其他流动负债

   流动负债合计                                                  13,970,182.86              126,061,449.65

非流动负债:

  长期借款

  长期应付款

  长期应付职工薪酬

  预计负债

  递延收益

  递延所得税负债

  其他非流动负债                                                 10,000,000.00               10,000,000.00

   非流动负债合计                                                10,000,000.00               10,000,000.00

     负债合计                                                    23,970,182.86              136,061,449.65

所有者权益(或股东权益)

  实收资本(或股本)                                            352,878,988.00              353,111,304.00

  其他权益工具

  其中:优先股

         永续债

  资本公积                                                  3,037,238,037.26              3,037,005,722.26

  减:库存股

  其他综合收益

  专项储备

  盈余公积

  未分配利润                                                    -552,656,046.33            -620,340,013.63

    所有者权益(或股东权益)合计                            2,837,460,978.93              2,769,777,012.63

     负债和所有者权益(或股东权益)总计                     2,861,431,161.79              2,905,838,462.28




法定代表人:张斌                   主管会计工作负责人:傅淑红                     会计机构负责人:侯宽余




                                                  13
                                                        广誉远中药股份有限公司 2018 年第三季度报告


                                               合并利润表
                                               2018 年 1—9 月
  编制单位:广誉远中药股份有限公司

                                                                           单位:元 币种:人民币 审计类型:未经审计

                                                                                                     上年年初至报告
                                                 本期金额          上期金额       年初至报告期期末
                          项目                                                                         期期末金额
                                                 (7-9 月)       (7-9 月)       金额(1-9 月)
                                                                                                       (1-9 月)

一、营业总收入                                 366,571,226.13    234,033,640.36   1,021,622,356.72   737,759,372.65

其中:营业收入                                 366,571,226.13    234,033,640.36   1,021,622,356.72   737,759,372.65

      利息收入

      已赚保费

      手续费及佣金收入

二、营业总成本                                 264,615,576.15    203,250,129.07     742,452,015.36   601,949,436.21

其中:营业成本                                  66,424,135.24     39,892,150.49     181,886,151.23   148,419,380.66

      利息支出

      手续费及佣金支出

      退保金

      赔付支出净额

      提取保险合同准备金净额

      保单红利支出

      分保费用

      税金及附加                                 5,508,162.74      3,475,749.75      15,293,865.69    14,413,187.23

      销售费用                                 151,738,934.33    129,848,308.34     424,603,735.73   351,783,075.00

      管理费用                                  25,141,085.46     27,186,220.93      73,115,795.11    76,239,310.36

      研发费用                                  11,769,343.18      1,608,032.85      27,670,821.25     5,091,901.92

      财务费用                                   4,033,915.20      1,239,666.71       9,036,396.86     1,913,053.98

      其中:利息费用                             4,209,185.45      1,316,192.58       9,625,160.65     2,838,787.13

               利息收入                           -200,415.22       -219,205.11        -679,238.15     -1,135,193.09

      资产减值损失                                                                   10,845,249.49     4,089,527.06

  加:其他收益                                                                          536,000.00

投资收益(损失以“-”号填列)                    -605,710.85      2,649,904.08       1,065,582.82     1,074,589.07

      其中:对联营企业和合营企业的投资收益        -605,710.85                        -1,559,417.18     -1,575,315.01

      公允价值变动收益(损失以“-”号填列)

      资产处置收益(损失以“-”号填列)              -522.84        -11,474.01         -39,800.54       515,050.70




                                                      14
                                                              广誉远中药股份有限公司 2018 年第三季度报告


      汇兑收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                    101,349,416.29    33,421,941.36   280,732,123.64   137,399,576.21

  加:营业外收入                                           10,000.00       78,947.37      1,064,308.90     6,767,306.80

  减:营业外支出                                         812,696.49       260,610.30       893,770.71       545,873.78

四、利润总额(亏损总额以“-”号填列)                100,546,719.80    33,240,278.43   280,902,661.83   143,621,009.23

  减:所得税费用                                       15,711,156.58     7,541,216.63    44,157,732.56    33,809,756.11

五、净利润(净亏损以“-”号填列)                     84,835,563.22    25,699,061.80   236,744,929.27   109,811,253.12

 (一)按经营持续性分类

     1.持续经营净利润(净亏损以“-”号填列)          84,835,563.22    25,699,061.80   236,744,929.27   109,811,253.12

     2.终止经营净利润(净亏损以“-”号填列)

 (二)按所有权归属分类

     1.归属于母公司所有者的净利润                      81,729,908.50    24,917,836.68   225,978,885.45   103,593,685.26

     2.少数股东损益                                     3,105,654.72      781,225.12     10,766,043.82     6,217,567.86

六、其他综合收益的税后净额

  归属母公司所有者的其他综合收益的税后净额

    (一)不能重分类进损益的其他综合收益

      1.重新计量设定受益计划变动额

      2.权益法下不能转损益的其他综合收益

    (二)将重分类进损益的其他综合收益

      1.权益法下可转损益的其他综合收益

      2.可供出售金融资产公允价值变动损益

      3.持有至到期投资重分类为可供出售金融资产损益

      4.现金流量套期损益的有效部分

      5.外币财务报表折算差额

  归属于少数股东的其他综合收益的税后净额

七、综合收益总额                                       84,835,563.22    25,699,061.80   236,744,929.27   109,811,253.12

  归属于母公司所有者的综合收益总额                     81,729,908.50    24,917,836.68   225,978,885.45   103,593,685.26

  归属于少数股东的综合收益总额                          3,105,654.72      781,225.12     10,766,043.82     6,217,567.86

八、每股收益:

  (一)基本每股收益(元/股)                                      0.23            0.07             0.64             0.29

  (二)稀释每股收益(元/股)                                      0.23            0.07             0.64             0.29



    法定代表人:张斌                            主管会计工作负责人:傅淑红                 会计机构负责人:侯宽余




                                                            15
                                                         广誉远中药股份有限公司 2018 年第三季度报告


                                                 母公司利润表
                                                 2018 年 1—9 月

编制单位:广誉远中药股份有限公司
                                                                           单位:元 币种:人民币 审计类型:未经审计

                                                                                                      上年年初至报告
                                                    本期金额        上期金额       年初至报告期期末
                          项目                                                                         期期末金额
                                                   (7-9 月)      (7-9 月)       金额(1-9 月)
                                                                                                        (1-9 月)

一、营业收入                                       4,612,104.35    6,546,808.81       15,760,596.90    19,368,550.11

  减:营业成本

      税金及附加                                                    -193,216.11           41,253.25       887,443.38

      销售费用

      管理费用                                     9,690,535.17    8,331,148.97       27,521,578.96    26,619,745.01

      研发费用

      财务费用                                       -11,906.91        -2,952.46         -26,725.45      -129,463.30

      其中:利息费用

               利息收入                              -12,200.91        -3,846.73         -28,562.63      -133,464.93

      资产减值损失                                                                                       -992,937.30

  加:其他收益

      投资收益(损失以“-”号填列)              79,460,000.00                       79,460,000.00

      其中:对联营企业和合营企业的投资收益

      公允价值变动收益(损失以“-”号填列)

      资产处置收益(损失以“-”号填列)                -522.84                             -522.84       614,706.48

二、营业利润(亏损以“-”号填列)                74,392,953.25    -1,588,171.59      67,683,967.30     -6,401,531.20

  加:营业外收入

  减:营业外支出

三、利润总额(亏损总额以“-”号填列)            74,392,953.25    -1,588,171.59      67,683,967.30     -6,401,531.20

    减:所得税费用

四、净利润(净亏损以“-”号填列)                74,392,953.25    -1,588,171.59      67,683,967.30     -6,401,531.20

  (一)持续经营净利润(净亏损以“-”号填列)    74,392,953.25    -1,588,171.59      67,683,967.30     -6,401,531.20

  (二)终止经营净利润(净亏损以“-”号填列)

五、其他综合收益的税后净额

  (一)不能重分类进损益的其他综合收益

    1.重新计量设定受益计划变动额

   2.权益法下不能转损益的其他综合收益




                                                       16
                                                           广誉远中药股份有限公司 2018 年第三季度报告


  (二)将重分类进损益的其他综合收益

    1.权益法下可转损益的其他综合收益

    2.可供出售金融资产公允价值变动损益

    3.持有至到期投资重分类为可供出售金融资产损益

    4.现金流量套期损益的有效部分

    5.外币财务报表折算差额

六、综合收益总额                                    74,392,953.25     -1,588,171.59   67,683,967.30   -6,401,531.20

七、每股收益:

    (一)基本每股收益(元/股)

    (二)稀释每股收益(元/股)




法定代表人:张斌                         主管会计工作负责人:傅淑红                     会计机构负责人:侯宽余




                                                         17
                                                   广誉远中药股份有限公司 2018 年第三季度报告


                                         合并现金流量表
                                            2018 年 1-9 月
编制单位:广誉远中药股份有限公司
                                                             单位:元   币种:人民币   审计类型:未经审计

                               项目                              年初至报告期期末      上年年初至报告期期

                                                                  金额(1-9月)         末金额(1-9 月)

一、经营活动产生的现金流量:

  销售商品、提供劳务收到的现金                                     501,671,759.47          460,673,854.36

  客户存款和同业存放款项净增加额

  向中央银行借款净增加额

  向其他金融机构拆入资金净增加额

  收到原保险合同保费取得的现金

  收到再保险业务现金净额

  保户储金及投资款净增加额

  处置以公允价值计量且其变动计入当期损益的金融资产净增加额

  收取利息、手续费及佣金的现金

  拆入资金净增加额

  回购业务资金净增加额

  收到的税费返还                                                        280,100.00

  收到其他与经营活动有关的现金                                      36,130,067.36           98,517,171.07

   经营活动现金流入小计                                            538,081,926.83          559,191,025.43

  购买商品、接受劳务支付的现金                                      80,722,372.38          127,554,561.70

  客户贷款及垫款净增加额

  存放中央银行和同业款项净增加额

  支付原保险合同赔付款项的现金

  支付利息、手续费及佣金的现金

  支付保单红利的现金

  支付给职工以及为职工支付的现金                                   121,025,341.35           90,905,093.92

  支付的各项税费                                                   204,206,131.17          153,706,871.49

  支付其他与经营活动有关的现金                                     402,037,174.35          413,195,119.64

   经营活动现金流出小计                                            807,991,019.25          785,361,646.75

     经营活动产生的现金流量净额                                    -269,909,092.42        -226,170,621.32

二、投资活动产生的现金流量:

  收回投资收到的现金                                               600,000,000.00          301,330,202.70



                                                 18
                                                     广誉远中药股份有限公司 2018 年第三季度报告


  取得投资收益收到的现金                                              5,554,166.67         3,450,000.00

  处置固定资产、无形资产和其他长期资产收回的现金净额                       157.50          1,562,073.04

  处置子公司及其他营业单位收到的现金净额

  收到其他与投资活动有关的现金

   投资活动现金流入小计                                             605,554,324.17       306,342,275.74

  购建固定资产、无形资产和其他长期资产支付的现金                    159,751,013.32       195,253,408.20

  投资支付的现金                                                    300,000,000.00       600,000,000.00

  质押贷款净增加额

  取得子公司及其他营业单位支付的现金净额

  支付其他与投资活动有关的现金                                       19,200,001.00

   投资活动现金流出小计                                             478,951,014.32       795,253,408.20

     投资活动产生的现金流量净额                                     126,603,309.85      -488,911,132.46

三、筹资活动产生的现金流量:

  吸收投资收到的现金                                                                         550,000.00

  其中:子公司吸收少数股东投资收到的现金

  取得借款收到的现金                                                322,121,750.00        30,000,000.00

  发行债券收到的现金

  收到其他与筹资活动有关的现金

   筹资活动现金流入小计                                             322,121,750.00        30,550,000.00

  偿还债务支付的现金                                                239,056,865.39        40,000,000.00

  分配股利、利润或偿付利息支付的现金                                 20,773,544.89           970,678.32

  其中:子公司支付给少数股东的股利、利润

  支付其他与筹资活动有关的现金

   筹资活动现金流出小计                                             259,830,410.28        40,970,678.32

     筹资活动产生的现金流量净额                                      62,291,339.72       -10,420,678.32

四、汇率变动对现金及现金等价物的影响

五、现金及现金等价物净增加额                                        -81,014,442.85      -725,502,432.10

  加:期初现金及现金等价物余额                                      280,946,210.16       968,463,899.81

六、期末现金及现金等价物余额                                        199,931,767.31       242,961,467.71




法定代表人:张斌                       主管会计工作负责人:傅淑红             会计机构负责人:侯宽余




                                                   19
                                                    广誉远中药股份有限公司 2018 年第三季度报告


                                       母公司现金流量表
                                           2018 年 1—9 月

编制单位:广誉远中药股份有限公司
                                                              单位:元    币种:人民币   审计类型:未经审计

                                                             年初至报告期期末金额     上年年初至报告期期末
                           项目
                                                                  (1-9月)              金额(1-9 月)

一、经营活动产生的现金流量:

  销售商品、提供劳务收到的现金

  收到的税费返还

  收到其他与经营活动有关的现金                                     405,766,166.49            239,255,996.47

   经营活动现金流入小计                                            405,766,166.49            239,255,996.47

  购买商品、接受劳务支付的现金

  支付给职工以及为职工支付的现金                                     8,877,671.62              8,493,448.51

  支付的各项税费                                                         364,274.14            1,251,835.53

  支付其他与经营活动有关的现金                                     433,958,016.44            238,313,374.00

   经营活动现金流出小计                                            443,199,962.20            248,058,658.04

  经营活动产生的现金流量净额                                       -37,433,795.71             -8,802,661.57

二、投资活动产生的现金流量:

  收回投资收到的现金                                                11,605,000.00

  取得投资收益收到的现金                                            57,000,000.00

  处置固定资产、无形资产和其他长期资产收回的现金净额                                           1,550,000.00

  处置子公司及其他营业单位收到的现金净额

  收到其他与投资活动有关的现金

   投资活动现金流入小计                                             68,605,000.00              1,550,000.00

  购建固定资产、无形资产和其他长期资产支付的现金                          89,179.97               45,313.00

  投资支付的现金                                                    15,900,000.00            836,211,112.00

  取得子公司及其他营业单位支付的现金净额

  支付其他与投资活动有关的现金                                      19,200,001.00

   投资活动现金流出小计                                             35,189,180.97            836,256,425.00

     投资活动产生的现金流量净额                                     33,415,819.03           -834,706,425.00

三、筹资活动产生的现金流量:

  吸收投资收到的现金

  取得借款收到的现金

  发行债券收到的现金



                                                   20
                                                      广誉远中药股份有限公司 2018 年第三季度报告


  收到其他与筹资活动有关的现金

   筹资活动现金流入小计

  偿还债务支付的现金

  分配股利、利润或偿付利息支付的现金

  支付其他与筹资活动有关的现金

   筹资活动现金流出小计

     筹资活动产生的现金流量净额

四、汇率变动对现金及现金等价物的影响

五、现金及现金等价物净增加额                                        -4,017,976.68       -843,509,086.57

  加:期初现金及现金等价物余额                                      17,318,905.84        853,759,712.10

六、期末现金及现金等价物余额                                        13,300,929.16         10,250,625.53


法定代表人:张斌                       主管会计工作负责人:傅淑红               会计机构负责人:侯宽余




4.2 审计报告
□适用 √不适用




                                                    21
数据加载中...
prevnext
手机查看股票